Ferritin, C-Reactive Protein, and Soluble CD25 Distinguish TAFRO From HLH
Steven Rowe1, Mariam Goubran2, Mateo Sarmiento Bustamante3
1Discipline of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
American Journal of Hematology
|September 26, 2025
Summary
This study introduces a clinical pathway to distinguish TAFRO syndrome from Hemophagocytic Lymphohistiocytosis (HLH) during a cytokine storm. It utilizes key biomarkers including ferritin, C-reactive protein, and soluble CD25 for accurate differentiation.
Area of Science:
- Hematology
- Immunology
- Clinical Medicine
Background:
- Cytokine storm syndromes, including Hemophagocytic Lymphohistiocytosis (HLH) and TAFRO syndrome, present overlapping clinical features.
- Accurate differentiation is crucial for appropriate therapeutic strategies and improved patient outcomes.
- Distinguishing between these conditions can be challenging due to similar inflammatory markers.
